Invention Grant
- Patent Title: Deuterated caffeine and uses thereof
-
Application No.: US17618855Application Date: 2020-06-12
-
Publication No.: US11666073B2Publication Date: 2023-06-06
- Inventor: Bradford C. Sippy
- Applicant: Lennham Pharmaceuticals, Inc.
- Applicant Address: US MA Concord
- Assignee: Lennham Pharmaceuticals, Inc.
- Current Assignee: Lennham Pharmaceuticals, Inc.
- Current Assignee Address: US MA Concord
- Agency: Wolf, Greenfield & Sacks, P.C.
- International Application: PCT/US2020/037485 2020.06.12
- International Announcement: WO2020/252302A 2020.12.17
- Date entered country: 2021-12-13
- Main IPC: A23L27/30
- IPC: A23L27/30 ; A23L27/20 ; A23L27/21 ; A23L27/00 ; A23L33/15 ; A23L33/175 ; A23L2/56 ; A23L2/60

Abstract:
Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
Public/Granted literature
- US20220248720A1 DEUTERATED CAFFEINE AND USES THEREOF Public/Granted day:2022-08-11
Information query